Literature DB >> 22037693

Targeting angiogenesis in gastroesophageal cancer: industry-sponsored trials are not the answer.

Sarah K Thompson1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22037693     DOI： 10.1007/s00268-011-1324-z

Source DB:  PubMed          Journal:  World J Surg        ISSN： 0364-2313            Impact factor:   3.352


× No keyword cloud information.
  9 in total

1.  Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.

Authors:  Yung-Jue Bang; Eric Van Cutsem; Andrea Feyereislova; Hyun C Chung; Lin Shen; Akira Sawaki; Florian Lordick; Atsushi Ohtsu; Yasushi Omuro; Taroh Satoh; Giuseppe Aprile; Evgeny Kulikov; Julie Hill; Michaela Lehle; Josef Rüschoff; Yoon-Koo Kang
Journal:  Lancet       Date:  2010-08-19       Impact factor: 79.321

2.  Isolated tumor cells in esophageal cancer: implications for the surgeon and the pathologist.

Authors:  Sarah K Thompson; Andrew R Ruszkiewicz; Glyn G Jamieson; Thomas R Sullivan; Peter G Devitt
Journal:  Ann Surg       Date:  2010-08       Impact factor: 12.969

Review 3.  Cardiotoxicity of tyrosine-kinase-targeting drugs.

Authors:  A Garcia-Alvarez; X Garcia-Albeniz; J Esteve; M Rovira; X Bosch
Journal:  Cardiovasc Hematol Agents Med Chem       Date:  2010-01

4.  Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study.

Authors:  Atsushi Ohtsu; Manish A Shah; Eric Van Cutsem; Sun Young Rha; Akira Sawaki; Sook Ryun Park; Ho Yeong Lim; Yasuhide Yamada; Jian Wu; Bernd Langer; Michal Starnawski; Yoon-Koo Kang
Journal:  J Clin Oncol       Date:  2011-08-15       Impact factor: 44.544

Review 5.  Clinicopathologic factors associated with HER2-positive gastric cancer and its impact on survival outcomes--a systematic review.

Authors:  Terence C Chua; Neil D Merrett
Journal:  Int J Cancer       Date:  2011-11-17       Impact factor: 7.396

6.  Correlation of vascular endothelial growth factor expression with tumor recurrence and poor prognosis in patients with pN0 gastric cancer.

Authors:  Yan-Feng Liu; Sen Guo; Rui Zhao; Yue-Guang Chen; Xian-Qiang Wang; Ke-Sen Xu
Journal:  World J Surg       Date:  2012-01       Impact factor: 3.352

Review 7.  Biology of angiogenesis in tumors of the gastrointestinal tract.

Authors:  Niels Reinmuth; Alexander A Parikh; Syed A Ahmad; Wenbiao Liu; Oliver Stoeltzing; Fan Fan; Akihiko Takeda; Morihisa Akagi; Lee M Ellis
Journal:  Microsc Res Tech       Date:  2003-02-01       Impact factor: 2.769

8.  Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.

Authors:  Herbert Hurwitz; Louis Fehrenbacher; William Novotny; Thomas Cartwright; John Hainsworth; William Heim; Jordan Berlin; Ari Baron; Susan Griffing; Eric Holmgren; Napoleone Ferrara; Gwen Fyfe; Beth Rogers; Robert Ross; Fairooz Kabbinavar
Journal:  N Engl J Med       Date:  2004-06-03       Impact factor: 91.245

Review 9.  Targeting angiogenesis in esophagogastric adenocarcinoma.

Authors:  Alicia F C Okines; Andrew R Reynolds; David Cunningham
Journal:  Oncologist       Date:  2011-05-31
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.